NIAID Unveils First Year Results of US Government “Combating Antibiotic Resistant Behaviour (CARB) Initiative” at Superbugs USA

NIAID Unveils First Year Results of US Government “Combating Antibiotic Resistant Behaviour (CARB) Initiative” at Superbugs USA

In just over 4 weeks on November 14th & 15th, SMi Group will open its doors to host the highly anticipated conference on antimicrobial resistance (AMR) – Superbugs & Superdrugs USA 2016.

By reaffirming the World Health Organisation’s “Global Action Plan on Antimicrobial Resistance” and recognizing the severe and imperative threat posed by AMR, a recent UN declaration adds a level of political pressure committing countries to facilitate policy and take action on making AMR a priority.

Running for almost two decades in Europe, SMi Group has taken the initiative to travel to North America with its Superbugs series of events to discuss what health experts have warned, a threat that will go beyond national borders and have the capacity to kill millions each year.

Highlights will include an exclusive address from Dr Rosmarie Aurigemma, Chief of the Biodefense Drug Development Section at the National Institute of Allergy and Infectious Diseases (NIAID). Through illustrated examples, the presentation will describe NIAID programs that support antibacterial product development; reveal results from the first year of the CARB initiative; and provide progressive insight into future opportunities.

In addition to their keynote address, the NIAID will then go onto host a post conference workshop on Nov 16th led by Tina Guina. The interactive session will discuss funding opportunities provided by the US Government and delve deeper into clinical and regulatory challenges surrounding antibacterial drug development.

With over twenty-five years of experience in infectious disease research and product development, Dr. Tina Guina is a Therapeutics Development Project Officer at the NIAID. She currently manages NIAID contracts awarded for the development of antibacterial therapeutics and is also a co-chair/member of the US Government committees on biodefense preparedness and response.

The NIAID workshop will feature additional input from: Francois Franceschi, Therapeutics Development Program Officer at the NIAID; Ian Friedland, Chief Medical Officer at Achaogen; John Tomayko, Chief Medical Officer from Spero Therapeutic; Christopher Houchens, Branch Chief of BARDA’S Antibacterials Program; and Thomas Lodise, Professor of Pharmacy Practice at the Albany College of Pharmacy and Health Sciences.

AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping?

Gathering an international audience of senior industry thought leaders, scientific pioneers and government bodies such as John Rex (AstraZeneca), PAHO/WHO, BARDA and Janssen, the Superbugs and Superdrugs USA conference will address key questions such as:

• Has progress been made with the “Global Action Plan on Antimicrobial Resistance” – what is the next strategic line in moving forward?
• How is National Strategy boosting drug discovery and investment?
• What progress has been made with the development of clinical assets through collaborative ventures?
• How are scientists looking at new pathways and tools to enable drug discovery?
• What can be learnt from Phase I European clinical trials on a new class of macrocycle antibiotics?
• How can gram-positive antibiotics be turned into gram-negative therapeutics?
• Can resistant gene products be targeted using protein "resistance neutralizers"?
• What is being done to tackle zoonotic diseases?
• Combination therapy use v disuse - What are the advantages and disadvantages of combining anti-microbial agents?

Further information on both the conference and interactive workshops is available at www.superbugs-usa.com

A series of interviews with keynote speakers is also available to read in the event download centre at http://www.smi-online.co.uk/2016superbugsusa.asp#tab_downloads

Superbugs & Superdrugs USA 2016
Conference: Nov 14 – 15
Interactive workshops: Nov 16
Renaissance Woodbridge Hotel, Iselin, New Jersey

---end ---

Source:
http://www.un.org/pga/71/2016/09/21/opening-remarks-at-high-level-meeting-on-antimicrobial-resistance/

Contact Information:

For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit http://www.superbugs-usa.com or contact Matthew Apps on Tel: +44 (0)20 7827 6093 / Email: mapps@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 / Email: amalick@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

2 Floor Harling House
47-51 Great Suffolk Street

This release was published on openPR.